Neurocrine ending development of luvadaxistat amid failed study (NASDAQ:NBIX)09/13/2024 Devonyu Neurocrine Biosciences (NASDAQ:NBIX) has halted development of luvadaxistat as a result of disappointing outcomes from a Phase 2 study of the drug within the remedy…
